From:  The role of eosinophils in the management of acute paediatric wheeze: a scoping review

 Summary of eosinophil values reported during acute wheeze exacerbations across 8 studies.

ReferenceHolden et al. [27]Kocak et al. [28]Elkharwili et al. [29]Li et al. [30]Gileles-Hillel et al. [31]Kim et al. [32]Jartti et al. [16]Jartti et al. [15]
Population sub-groupsAcuteControlAcuteControlG1G2G3AcuteStableControlDexamethasoneBetamethosoneN/ARVRSVPredPlacebo
Eosinophil count unit/metric/values× 109/L**
Median (range)		× 109/L**
Mean ± SD		Eosinophil %*
Mean ± SD		Eosinophil %*
Median (p25/p75)		× 109/L**
Median (IQR)		× 109/L**
Mean ± SD		× 109/L**
Mean ± SD
0.1 (0.00–2.41)
Stable
(n = 20)
0.43 (0.12–1.5)		0.17 (0.00–0.83)Day 1: 0.61 ± 0.43
Day 5: 0.16 ± 0.09		0.12 ± 0.068.80 ± 4.998.25 ± 4.478.15 ± 4.633.8 (2.65–4.75)2.7 (1.8–4.05)2.2 (1.30–3.85)0.1 (0.00–0.3)0.04 (0.00–0.2)0.34 ± 0.340.44 ± 0.290.09 ± 0.190.51 ± 0.450.51 ± 0.38
Eosinophil cut-off0.3 × 109/L**Not used/reportedNot used/reportedNot used/reportedNot used/reported0.3 × 109/L**0.2 × 109/L**0.4 × 109/L**
The percentage of samples above the cut-off value (%)7103252 (n = 67)5057
Sample timingED Department with < 24 hours of SCS therapy
Stable: > 4weeks after acute		On admissionOn admissionDay 1 (admission) + 5 days post steroidsAdmission (prior to treatment)In clinicOn arrivalPrior to treatment Prior to randomisation on wardPrior to randomisation
Return to article view

Results reported to 2 dp. *: Studies with eosinophil percentage reported were also identified to have a discrepancy in reporting units between tables within their publications; **: units reported in different units but converted to cell counts (× 109/L) for consistency. N/A: not available; RSV: respiratory syncytial virus; RV: rhinovirus; SCS: systemic corticosteroids.